|
|
|
|
||
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic LeukemiaData Show High Rates of Response to Single Infusion of KTE-X19 - Phase 2 Portion of ZUMA-3 is Ongoing and Includes Dosing and Revised Safety Management Protocol Studied in Phase 1 https://www.marketwatch.com/press-release/kite-announces-end-of-phase-1-zuma-3-results-for-kte-x19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-2019-06-01 |
return to message board, top of board |